However, this drug has been associated with an increasing number of reported neuropsychiatric adverse drug reactions (ADRs). ![]() ![]() The proposed applications include neuroinflammation control, which could be explored in some neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases (AD and PD). Recently, new molecular targets have been identified and MTK has been proposed for repurposing in other therapeutic applications, with several ongoing clinical trials. Increasing environmental distress is associated with a growing asthma incidence no treatments are available but montelukast (MTK)-an antagonist of the cysteinyl leukotrienes receptor 1-is widely used in the management of symptoms among adults and children.
0 Comments
Leave a Reply. |